advertisement
Lu F 36
Showing records 1 to 25 | Display all abstracts from Lu F80575 Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Aihara M
Journal of Glaucoma 2019; 28: 375-385
80887 Elevated Plasma Levels of Drebrin in Glaucoma Patients With Neurodegeneration
Gan YJ
Frontiers in neuroscience 2019; 13: 326
80886 Mutant RAMP2 causes primary open-angle glaucoma via the CRLR-cAMP axis
Gong B
Genetics in Medicine 2019; 21: 2345-2354
80887 Elevated Plasma Levels of Drebrin in Glaucoma Patients With Neurodegeneration
Fang AW
Frontiers in neuroscience 2019; 13: 326
80886 Mutant RAMP2 causes primary open-angle glaucoma via the CRLR-cAMP axis
Zhang H
Genetics in Medicine 2019; 21: 2345-2354
80575 Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Lu F
Journal of Glaucoma 2019; 28: 375-385
80887 Elevated Plasma Levels of Drebrin in Glaucoma Patients With Neurodegeneration
Liu C
Frontiers in neuroscience 2019; 13: 326
80886 Mutant RAMP2 causes primary open-angle glaucoma via the CRLR-cAMP axis
Huang L
Genetics in Medicine 2019; 21: 2345-2354
80575 Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Kawata H; Iwata A
Journal of Glaucoma 2019; 28: 375-385
80886 Mutant RAMP2 causes primary open-angle glaucoma via the CRLR-cAMP axis
Chen Y
Genetics in Medicine 2019; 21: 2345-2354
80887 Elevated Plasma Levels of Drebrin in Glaucoma Patients With Neurodegeneration
Liu BJ
Frontiers in neuroscience 2019; 13: 326
80575 Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Liu K
Journal of Glaucoma 2019; 28: 375-385
80886 Mutant RAMP2 causes primary open-angle glaucoma via the CRLR-cAMP axis
Shi Y
Genetics in Medicine 2019; 21: 2345-2354
80887 Elevated Plasma Levels of Drebrin in Glaucoma Patients With Neurodegeneration
Yang FM; Guan JT
Frontiers in neuroscience 2019; 13: 326
80886 Mutant RAMP2 causes primary open-angle glaucoma via the CRLR-cAMP axis
Tam PO
Genetics in Medicine 2019; 21: 2345-2354
80575 Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Odani-Kawabata N
Journal of Glaucoma 2019; 28: 375-385
80886 Mutant RAMP2 causes primary open-angle glaucoma via the CRLR-cAMP axis
Zhu X
Genetics in Medicine 2019; 21: 2345-2354
80575 Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Shams NK
Journal of Glaucoma 2019; 28: 375-385
80887 Elevated Plasma Levels of Drebrin in Glaucoma Patients With Neurodegeneration
Lan CL
Frontiers in neuroscience 2019; 13: 326
80886 Mutant RAMP2 causes primary open-angle glaucoma via the CRLR-cAMP axis
Huang Y
Genetics in Medicine 2019; 21: 2345-2354
80887 Elevated Plasma Levels of Drebrin in Glaucoma Patients With Neurodegeneration
Dai XD
Frontiers in neuroscience 2019; 13: 326
80886 Mutant RAMP2 causes primary open-angle glaucoma via the CRLR-cAMP axis
Lei B
Genetics in Medicine 2019; 21: 2345-2354
80887 Elevated Plasma Levels of Drebrin in Glaucoma Patients With Neurodegeneration
Li T; Cao Y
Frontiers in neuroscience 2019; 13: 326
80886 Mutant RAMP2 causes primary open-angle glaucoma via the CRLR-cAMP axis
Sundaresan P; Li X
Genetics in Medicine 2019; 21: 2345-2354
80887 Elevated Plasma Levels of Drebrin in Glaucoma Patients With Neurodegeneration
Ran Y
Frontiers in neuroscience 2019; 13: 326
